SCHEMBL89376

SCHEMBL89376

COCCCCOc1cc(OC)cc(C(=O)O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 1/20 0.66
NPC1 O15118 1/20 0.51
RECQL P46063 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 2/20 0.47
RXRA P19793 1/20 0.47
FFAR1 O14842 1/20 0.47
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
MEN1 O00255 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
POLB P06746 1/20 0.45
KDM4E B2RXH2 2/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
GAA P10253 1/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL56353 0.97 PLA2G2A (0.61) PLA2G2ANPC1RECQLRAB9AKMT2A
SCHEMBL29788135 0.92 PLA2G2A (0.58) PLA2G2ANPC1RECQLRAB9AKMT2A
SCHEMBL90428 0.92 PLA2G2A (0.58) PLA2G2ANPC1RECQLRAB9AKMT2A
SCHEMBL3487150 0.91 PLA2G2A (0.67) PLA2G2ANPC1RECQLRAB9AKMT2A
SCHEMBL11254541 0.87 PLA2G2A (0.88) PLA2G2AKMT2ATP53TSHR
SCHEMBL10263820 0.87 PLA2G2A (0.76) PLA2G2AKMT2ATP53TSHR
SCHEMBL23352170 0.86 PLA2G2A (0.64) PLA2G2ANPC1RECQLRAB9AKMT2A
SCHEMBL13461246 0.85 PLA2G2A (0.73) PLA2G2AKMT2ATP53TSHR
SCHEMBL89656 0.85 RAB9A (0.50) PLA2G2ANPC1RECQLRAB9AKMT2A
SCHEMBL14812353 0.85 PLA2G2A (0.58) PLA2G2ANPC1RECQLRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 PLA2G2A 3728/4885NPC1 2676/4885RECQL 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.